Centre of Evidence Based Dermatology
  • Print

CEBD Coronavirus Dermatology Resource

 

Journal articles - Coronavirus and specific patient groups

Contents

Psoriasis

Atopic dermatitis

Skin cancers

Hidradenitis suppurativa

Bullous diseases

Paediatric

Other conditions and groups

Please see also Guidelines page 

 

Psoriasis

See also Implications of coronavirus for use of biologics and other immune modulating therapies

Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries.
Gadarowski MB, Balogh EA, Bashyam AM, Feldman SR.
J Dermatolog Treat. 2020 Aug 8:1-17. doi: 10.1080/09546634.2020.1808154. Online ahead of print. Review.
https://doi.org/10.1080/09546634.2020.1808154

Biologic drugs during COVID-19 outbreak.
Montesu MA, Biondi G, Sotgiu G, Sucato F, Satta R.
Int J Dermatol. 2020 Aug 6. doi: 10.1111/ijd.15088. Online ahead of print. Cohort study.
https://doi.org/10.1111/ijd.15088

COVID-19 and immunosuppressive therapy in dermatology.
Schwartz RA, Pradhan S, Murrell DF, Jafferany M, Olisova OY, Lomonosov KM, Lotti T, Goldust M.
Dermatol Ther. 2020 Aug 7:e14140. doi: 10.1111/dth.14140. Online ahead of print. Review / recommendations.
https://doi.org/10.1111/dth.14140

Severe acute respiratory syndrome coronavirus 2 and the use of biologics in patients with psoriasis.
Ladda M, Lynde C, Fleming P.
J Cutan Med Surg. 2020 Aug 6:1203475420945234. doi: 10.1177/1203475420945234. Online ahead of print. Review.
https://doi.org/10.1177/1203475420945234

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy.
Talamonti M, Galluzzo M, Chiricozzi A, Quaglino P, Fabbrocini G, Gisondi P, Marzano AV, Potenza C, Conti A, Parodi A, Belloni Fortina A, Bardazzi F, Argenziano G, Rongioletti F, Stingeni L, Micali G, Loconsole F, Venturini M, Bongiorno MR, Feliciani C, Rubegni P, Amerio P, Fargnoli MC, Pigatto P, Savoia P, Nisticò SP, Giustini S, Carugno A, Cannavò SP, Rech G, Prignano F, Offidani A, Lombardo M, Zalaudek I, Bianchi L, Peris K; PSO-BIO-COVID study group.
J Eur Acad Dermatol Venereol. 2020 Jul 31. doi: 10.1111/jdv.16841. Online ahead of print. Multicentre observational study.
https://doi.org/10.1111/jdv.16841

COVID-19 and implications for dermatological and allergological diseases.
Buhl T, Beissert S, Gaffal E, Goebeler M, Hertl M, Mauch C, Reich K, Schmidt E, Schön MP, Sticherling M, Sunderkötter C, Traidl-Hoffmann C, Werfel T, Wilsman-Theis D, Worm M.
J Dtsch Dermatol Ges. 2020 Jul 27. doi: 10.1111/ddg.14195. Online ahead of print. Review.
https://doi.org/10.1111/ddg.14195

How infodemic during the COVID-19 outbreak influenced common clinical practice in an Outpatient Service of severe psoriasis.
Sacchelli L, Evangelista V, Di Altobrando A, Lacava R, Rucci P, Rosa S, Patrizi A, Bardazzi F.
Dermatol Ther. 2020 Jul 26:e14065. doi: 10.1111/dth.14065. Online ahead of print. Prospective cohort study.
https://doi.org/10.1111/dth.14065

The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies.
Pirro F, Caldarola G, Chiricozzi A, Tambone S, Mariani M, Calabrese L, D'Urso DF, De Simone C, Peris K.
J Dermatolog Treat. 2020 Jul 24:1-14. doi: 10.1080/09546634.2020.1800578. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1080/09546634.2020.1800578

A case of severe psoriatic erythroderma with COVID-19.
Ghalamkarpour F, Pourani MR, Abdollahimajd F, Zargari O.
J Dermatolog Treat. 2020 Jul 21:1-11. doi: 10.1080/09546634.2020.1799918. Online ahead of print. Case report.
https://doi.org/10.1080/09546634.2020.1799918

Psoriasis and COVID-19: A narrative review with treatment considerations.
Elmas ÖF, Demirbaş A, Kutlu Ö, Bağcıer F, Metin MS, Özyurt K, Akdeniz N, Atasoy M, Türsen Ü, Lotti T.
Dermatol Ther. 2020 Jun 17:e13858. doi: 10.1111/dth.13858. Online ahead of print.
https://doi.org/10.1111/dth.13858

Treatment discontinuation and rate of disease transmission in psoriasis patients on biologic therapy during the COVID-19 pandemic - A Canadian multicenter retrospective study.
Georgakopoulos JR, Mufti A, Vender R, Yeung J.
J Am Acad Dermatol. 2020 Jul 14. pii: S0190-9622(20)32185-X. doi: 10.1016/j.jaad.2020.07.021. [Epub ahead of print] No abstract available. Retrospective study / case review.
https://doi.org/10.1016/j.jaad.2020.07.021

Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.
Vispi M, Corradin T, Peccianti C, Feci L, Casini L, Pisani C, Fabbroni S, Corsetti P, Croatto M, Pellegrino M.
Dermatol Reports. 2020 Jun 25;12(1):8642. doi: 10.4081/dr.2020.8642. eCollection 2020 Jun 25. Report / audit.
https://doi.org/10.4081/dr.2020.8642

Coronavirus disease 2019 (COVID-19) rash in a psoriatic patient treated with Secukinumab: is there a role for Interleukin 17?
Carugno A, Gambini DM, Raponi F, Vezzoli P, Robustelli Test E, Arosio MEG, Callegaro A, Sena P.
Dermatol Ther. 2020 Jul 12:e14011. doi: 10.1111/dth.14011. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.14011

Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?
Talamonti M, Tofani L, Bianchi L, Galluzzo M.
Arch Dermatol Res. 2020 Jul 9. doi: 10.1007/s00403-020-02103-z. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1007/s00403-020-02103-z

Patient´s perspective: psychological burden of the COVID-19 pandemic in 146 psoriatic patients treated with biological drugs and small molecules in real clinical practice.
Rodríguez-Villa Lario A, Vega-Díez D, González-Cañete M, Polo-Rodríguez I, Piteiro-Bermejo AB, Herrero-Fernández M, Arévalo-Serrano J, Trasobares-Marugán L, Medina-Montalvo S.
J Dermatolog Treat. 2020 Jul 9:1-9. doi: 10.1080/09546634.2020.1790485. [Epub ahead of print] No abstract available. Retrospective chart review.
https://doi.org/10.1080/09546634.2020.1790485

Risk of COVID-19 in dermatologic patients on long-term immunomodulatory therapy.
Holcomb ZE, Santillan MR, Morss-Walton PC, Salian P, Her MJ, Giannotti NM, Kimball AB, Porter ML.
J Am Acad Dermatol. 2020 Jul 1. pii: S0190-9622(20)32099-5. doi: 10.1016/j.jaad.2020.06.999. [Epub ahead of print] No abstract available. Retrospective cross-sectional study.
https://doi.org/10.1016/j.jaad.2020.06.999

The risk of respiratory tract infections in psoriasis patients treated with IL-23-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic.
Syed MN, Shin DB, Wan MT, Winthrop KL, Gelfand JM.
J Am Acad Dermatol. 2020 Jul 2. pii: S0190-9622(20)32115-0. doi: 10.1016/j.jaad.2020.06.1014. [Epub ahead of print] No abstract available. Meta-analysis.
https://doi.org/10.1016/j.jaad.2020.06.1014

COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy versus apremilast in North Spain.
Queiro Silva R, Armesto S, González Vela C, Naharro Fernández C, González-Gay MA.
Dermatol Ther. 2020 Jul 3:e13961. doi: 10.1111/dth.13961. [Epub ahead of print]. Case series.
https://doi.org/10.1111/dth.13961

Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: A multicenter study in the Czech Republic.
Rob F, Hugo J, Tivadar S, Boháč P, Gkalpakiotis S, Vargová N, Arenbergerová M, Hercogová J.
J Eur Acad Dermatol Venereol. 2020 Jun 27. doi: 10.1111/jdv.16771. [Epub ahead of print]. Prospective research study.
https://doi.org/10.1111/jdv.16771

COVID-19 and psoriasis: Biologic treatment and challenges.
Ebrahimi A, Sayad B, Rahimi Z.
J Dermatolog Treat. 2020 Jun 29:1-14. doi: 10.1080/09546634.2020.1789051. [Epub ahead of print]. Review.
https://doi.org/10.1080/09546634.2020.1789051

Treatment of psoriasis - unburdened by fear during SARS-CoV2 menace.
Timis TL, Florian IA, Vesa SC, Orasan RI.
J Dermatolog Treat. 2020 Jun 27:1-10. doi: 10.1080/09546634.2020.1788704. [Epub ahead of print]. Review / commentary.
https://doi.org/10.1080/09546634.2020.1788704

COVID-19 infection on IL-23 inhibition.
Wang CJ, Truong AK.
Dermatol Ther. 2020 Jun 25. doi: 10.1111/dth.13893. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13893

Psoriasis and COVID-19: a multifactorial consideration.
Cohen JM, Perez-Chada LM, De Kouchkovsky D, Gehlhausen JR.
J Dermatolog Treat. 2020 Jun 22:1. doi: 10.1080/09546634.2020.1782818. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1080/09546634.2020.1782818

Clinical management of psoriasis patients during the COVID-19 pandemic.
Chat VS, Uppal SK, Kearns DG, Wu JJ.
J Dermatolog Treat. 2020 Jun 22:1-2. doi: 10.1080/09546634.2020.1781045. [Epub ahead of print]. Review / commentary.
https://doi.org/10.1080/09546634.2020.1781045

Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19.
Fougerousse AC, Perrussel M, Bécherel PA, Begon E, Pallure V, Zaraa I, Chaby G, Parier J, Kemula M, Mery-Bossard L, Poreaux C, Taieb C, Maccari F, Reguiai Z; GEM Resopso.
J Eur Acad Dermatol Venereol. 2020 Jun 21. doi: 10.1111/jdv.16761. [Epub ahead of print]. Multicentre, cross-sectional study.
https://doi.org/10.1111/jdv.16761

'Treatment adherence in psoriatic patients during COVID-19 pandemic: Real-world data from a tertiary hospital in Greece''.
Vakirlis AE, Bakirtzi K, Papadimitriou I, Vrani F, Sideris N, Lallas A, Ioannides D, Sotiriou E.
J Eur Acad Dermatol Venereol. 2020 Jun 18. doi: 10.1111/jdv.16759. [Epub ahead of print]. Survey / observational study.
https://doi.org/10.1111/jdv.16759

Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab.
Facheris P, Valenti M, Pavia G, Gargiulo L, Narcisi A, Costanzo A, Borroni RG.
Int J Dermatol. 2020 Jun 18. doi: 10.1111/ijd.15008. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/ijd.15008

Patients with specific skin disorders who are affected by COVID-19: what do experiences say about management strategies? : A systematic review.
Najar Nobar N, Goodarzi A.
Dermatol Ther. 2020 Jun 18:e13867. doi: 10.1111/dth.13867. [Epub ahead of print]. Systematic review.
https://doi.org/10.1111/dth.13867

Risk of infections in psoriasis. A lesson to learn during the SARS-CoV-2 pandemic.
Naldi L.
Br J Dermatol. 2020 Jun 15. doi: 10.1111/bjd.19190. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/bjd.19190

Psoriasis and risk of the COVID-19 infection: Is there a role for Angiotensin Converting Enzyme (ACE)?
Shahidi-Dadras M, Tabary M, Robati RM, Araghi F, Dadkhahfar S.
J Dermatolog Treat. 2020 Jun 16:1-7. doi: 10.1080/09546634.2020.1782819. [Epub ahead of print]. Commentary.
https://doi.org/10.1080/09546634.2020.1782819

Comment on "Psoriasis, COVID-19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment".
Farabi B, Bhargava S, Goldust M, Atak MF.
Dermatol Ther. 2020 Jun 14:e13840. doi: 10.1111/dth.13840. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13840

COVID-19 era: A chance to learn something new about monitoring psoriatic patients in biological therapy.
Filippi F, Loi C, Evangelista V, Bardazzi F.
Dermatol Ther. 2020 Jun 10:e13805. doi: 10.1111/dth.13805. [Epub ahead of print] No abstract available. Report / audit.
https://doi.org/10.1111/dth.13805

Biologic agents in psoriasis: our experience during coronavirus infection.
Strippoli D, Barbagallo T, Prestinari F, Russo G, Fantini F.
Int J Dermatol. 2020 Jun 9. doi: 10.1111/ijd.15002. [Epub ahead of print] No abstract available. Cross-sectional study.
https://doi.org/10.1111/ijd.15002

Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.
Jindal A, Ramesh S, Noronha M, Pai K, Pai S.
Dermatol Ther. 2020 Jun 8:e13787. doi: 10.1111/dth.13787. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13787 

Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.
Galluzzo M, Tofani L, Bianchi L, Talamonti M.
Expert Opin Biol Ther. 2020 Jun 8. doi: 10.1080/14712598.2020.1779217. [Epub ahead of print] No abstract available. Commentary/ cohort study.
https://doi.org/10.1080/14712598.2020.1779217

Psoriasis-COVID 19 infection: Treatment options.
Tampouratzi E, Kanni T, Katsantonis J, Douvali T.
Skinmed. 2020 Mar 1;18(2):81-82. eCollection 2020. No abstract available. Commentary?
https://pubmed.ncbi.nlm.nih.gov/32501789/

Recommendations for treatment of nail psoriasis during the COVID-19 pandemic.
Ricardo JW, Lipner SR.
Dermatol Ther. 2020 Jun 4:e13757. doi: 10.1111/dth.13757. [Epub ahead of print] No abstract available. Review / recommendations.
https://doi.org/10.1111/dth.13757

Rate of patient-driven biologic treatment discontinuation during the COVID-19 pandemic in 2 academic hospital clinics at the University of Toronto.
Georgakopoulos JR, Yeung J.
J Cutan Med Surg. 2020 Jun 1:1203475420930226. doi: 10.1177/1203475420930226. [Epub ahead of print] No abstract available. Multicentre retrospective case review.
https://doi.org/10.1177/1203475420930226

Psoriasis, biologic therapy, and the pandemic of the 21st century.
Nogueira M, Vender R, Torres T.
Drugs Context. 2020 May 14;9. pii: 2020-4-10. doi: 10.7573/dic.2020-4-10. eCollection 2020. Editorial.
https://doi.org/10.7573/dic.2020-4-10

Covid-19 infection in psoriasis patients treated with cyclosporin.
Di Lernia V, Goldust M, Feliciani C.
Dermatol Ther. 2020 Jun 1. doi: 10.1111/dth.13739. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1111/dth.13739

Psoriasis, COVID-19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment.
Magnano M, Balestri R, Bardazzi F, Mazzatenta C, Girardelli CR, Rech G.
Dermatol Ther. 2020 May 30. doi: 10.1111/dth.13706. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1111/dth.13706

Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult psoriasis during COVID-19 pandemic.
Melis D, Mugheddu C, Sanna S, Atzori L, Rongioletti F.
Dermatol Ther. 2020 May 30:e13722. doi: 10.1111/dth.13722. [Epub ahead of print]. Case series.
https://doi.org/10.1111/dth.13722

Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab.
Valenti M, Facheris P, Pavia G, Gargiulo L, Borroni RG, Costanzo A, Narcisi A.
Dermatol Ther. 2020 May 30. doi: 10.1111/dth.13708. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13708

Novel coronavirus disease (COVID-19) and biologic therapy for psoriasis: Successful recovery in two patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, Liao W.
Dermatol Ther (Heidelb). 2020 May 29. doi: 10.1007/s13555-020-00394-8. [Epub ahead of print]. Case reports.
https://doi.org/10.1007/s13555-020-00394-8

Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.
Ricardo JW, Lipner SR.
Dermatol Ther. 2020 May 27. doi: 10.1111/dth.13687. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13687

Use of systemic therapies for psoriasis in the COVID-19 era.
Kearns DG, Uppal S, Chat VS, Wu JJ.
J Dermatolog Treat. 2020 May 27:1-14. doi: 10.1080/09546634.2020.1775774. [Epub ahead of print]. Review of guidelines.
https://doi.org/10.1080/09546634.2020.1775774

Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.
Yu Olisova O, Anpilogova EM, Svistunova DA.
Dermatol Ther. 2020 May 24:e13668. doi: 10.1111/dth.13668. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13668

Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment.
Sachdeva M, Mufti A, Maliyar K, Lytvyn Y, Yeung J.
J Am Acad Dermatol. 2020 May 19. pii: S0190-9622(20)30942-7. doi: 10.1016/j.jaad.2020.05.074. [Epub ahead of print]. Systematic review.
https://doi.org/10.1016/j.jaad.2020.05.074

Covid-19 and exacerbation of psoriasis.
Ozaras R, Berk A, Ucar DH, Duman H, Kaya F, Mutlu H.
Dermatol Ther. 2020 May 20. doi: 10.1111/dth.13632. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13632

Patient-driven discontinuation of dupilumab during the COVID-19 pandemic in two academic hospital clinics at the University of Toronto.
Georgakopoulos JR, Yeung J.
J Cutan Med Surg. 2020 May 20:1203475420930223. doi: 10.1177/1203475420930223. [Epub ahead of print] No abstract available. Retrospective cross-sectional study.
https://doi.org/10.1177/1203475420930223

Opportunistic virus infections in psoriasis patients: the safer alternative of apremilast.
Armesto S, González Vela C, González López MA.
Dermatol Ther. 2020 May 18:e13618. doi: 10.1111/dth.13618. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13618

Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19.
Galimberti F, McBride J, Cronin M, Li Y, Fox J, Abrouk M, Herbst A, Kirsner RS.
Clin Dermatol. 2020 May 14. doi: 10.1016/j.clindermatol.2020.05.003. [Epub ahead of print]. Review / recommendations.
https://doi.org/10.1016/j.clindermatol.2020.05.003

The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic.
Wan MT, Shin DB, Winthrop KL, Gelfand JM.
J Am Acad Dermatol. 2020 May 13. pii: S0190-9622(20)30866-5. doi: 10.1016/j.jaad.2020.05.035. [Epub ahead of print] No abstract available. Meta-analysis.
https://doi.org/10.1016/j.jaad.2020.05.035

Association of outdoor activity restriction and income loss with patient-reported outcomes of psoriasis during the COVID-19 pandemic: A web-based survey.
Kuang Y, Shen M, Wang Q, Xiao Y, Lv C, Luo Y, Zhu W, Chen X.
J Am Acad Dermatol. 2020 May 11. pii: S0190-9622(20)30846-X. doi: 10.1016/j.jaad.2020.05.018. [Epub ahead of print] No abstract available. Survey / cross-sectional study.
https://doi.org/10.1016/j.jaad.2020.05.018

A survey of psoriasis patients on biologics during COVID-19: a single centre experience.
Burlando M, Carmisciano L, Cozzani E, Parodi A.
J Dermatolog Treat. 2020 May 14:1-3. doi: 10.1080/09546634.2020.1770165. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1080/09546634.2020.1770165

COVID-19 in an elderly patient treated with secukinumab.
Di Lernia V, Bombonato C, Motolese A.
Dermatol Ther. 2020 May 13:e13580. doi: 10.1111/dth.13580. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13580

Is the coronavirus (COVID-19) pandemic an indication to temporarily modify dermatological management plans?
Shanshal M.
J Drugs Dermatol. 2020 Apr 1;19(4):436. No abstract available. Commentary.
http://jddonline.com/articles/dermatology/S1545961620P0436X

Patient-driven discontinuation of apremilast during the COVID-19 pandemic in two Canadian academic hospital clinics and one community practice.
Georgakopoulos JR, Vender R, Yeung J. Multicenter retrospective study.
J Cutan Med Surg. 2020 May 12:1203475420928382. doi: 10.1177/1203475420928382. [Epub ahead of print]
https://doi.org/10.1177/1203475420928382

COVID-19 and biologics for psoriasis: a high-epidemic area experience - Bergamo, Lombardy, Italy.
Carugno A, Gambini DM, Raponi F, Vezzoli P, Locatelli AGC, Di Mercurio M, Test ER, Sena P.
J Am Acad Dermatol. 2020 May 6. pii: S0190-9622(20)30819-7. doi: 10.1016/j.jaad.2020.04.165. [Epub ahead of print] No abstract available. Case reports & commentary.
https://doi.org/10.1016/j.jaad.2020.04.165

COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.
Mugheddu C, Pizzatti L, Sanna S, Atzori L, Rongioletti F.
J Eur Acad Dermatol Venereol. 2020 May 9. doi: 10.1111/jdv.16625. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16625

Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs.
Conti A, Lasagni C, Bigi L, Pellacani G.
J Eur Acad Dermatol Venereol. 2020 May 7. doi: 10.1111/jdv.16587. [Epub ahead of print]. Case series.
https://doi.org/10.1111/jdv.16587

Improvement of SARS-CoV2 symptoms following guselkumab injection in a psoriatic patient.
Benhadou F, Del Marmol V.
J Eur Acad Dermatol Venereol. 2020 May 7. doi: 10.1111/jdv.16590. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16590

Covid-19 in immune-mediated inflammatory diseases - Case series from New York.
Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, Neimann A, Adhikari S, Hudesman D, Scher JU.
N Engl J Med. 2020 Apr 29. doi: 10.1056/NEJMc2009567. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1056/NEJMc2009567

Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?
Kutlu Ö, Metin A.
Dermatol Ther. 2020 May 5:e13509. doi: 10.1111/dth.13509. [Epub ahead of print]. Case series.
https://doi.org/10.1111/dth.13509

A challenging case of psoriasis flare-up after COVID-19 infection.
Nasiri S, Araghi F, Tabary M, Gheisari M, Mahboubi-Fooladi Z, Dadkhahfar S.
J Dermatolog Treat. 2020 May 2:1-6. doi: 10.1080/09546634.2020.1764904. [Epub ahead of print]. Case report.
https://doi.org/10.1080/09546634.2020.1764904

Biologic therapy for psoriasis during the COVID-19 outbreak: the choice is to weigh risks and benefits.
Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I.
Dermatol Ther. 2020 May 1:e13490. doi: 10.1111/dth.13490. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13490

Comment on "Antipsoriatic treatments during COVID-19 outbreak".
Abdelmaksoud A, Goldust M, Vestita M.
Dermatol Ther. 2020 May 1:e13491. doi: 10.1111/dth.13491. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13491

Dermatology patients' knowledge and concerns regarding their immunomodulatory medication during the COVID-19 pandemic.
Keeling E, Daly S, McKenna DB.
Dermatol Ther. 2020 May 1:e13488. doi: 10.1111/dth.13488. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1111/dth.13488

Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.
Mahil SK, Yiu ZZN, Mason KJ, Dand N, Coker B, Wall D, Fletcher G, Bosma A, Capon F, Iversen L, Langan SM, Di Meglio P, Musters A, Prieto-Merino D, Tsakok T, Warren RB, Flohr C, Spuls P, Griffiths CEM, Barker J, Irvine AD, Smith CH; Secure-AD, PsoPROTECT study groups.
Br J Dermatol. 2020 Apr 29. doi: 10.1111/bjd.19161. [Epub ahead of print]. Letter/commentary.
https://doi.org/10.1111/bjd.19161

The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience.
Gisondi P, Facheris P, Dapavo P, Piaserico S, Conti A, Naldi L, Cazzaniga S, Malagoli P, Costanzo A.
Br J Dermatol. 2020 Apr 28. doi: 10.1111/bjd.19158. [Epub ahead of print]. Multicentre observational study.
https://doi.org/10.1111/bjd.19158

Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment.
Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G.
J Am Acad Dermatol. 2020 Apr 21. pii: S0190-9622(20)30701-5. doi: 10.1016/j.jaad.2020.04.085. [Epub ahead of print] No abstract available.
https://doi.org/10.1016/j.jaad.2020.04.085

Immunomodulators and immunosuppressants in the era of SARS-CoV-2 - could laboratory tests be the missing link?
Alpalhão M, Filipe P.
J Dermatolog Treat. 2020 Apr 23:1-8. doi: 10.1080/09546634.2020.1760195. [Epub ahead of print] No abstract available.
https://doi.org/10.1080/09546634.2020.1760195

COVID-19 and psoriasis : should we fear for patients treated with biologics?
Amerio P, Prignano F, Giuliani F, Gualdi G.
Dermatol Ther. 2020 Apr 20. doi: 10.1111/dth.13434. [Epub ahead of print]
https://doi.org/10.1111/dth.13434

Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis: Infection risk and patient counseling in uncertain times.
Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, Liao W.
Dermatol Ther (Heidelb). 2020 Apr 16:1-11. doi: 10.1007/s13555-020-00377-9. [Epub ahead of print]
https://doi.org/10.1007/s13555-020-00377-9

Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis: Infection risk and patient counseling in uncertain times.
Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, Liao W.
Dermatol Ther (Heidelb). 2020 Apr 16. doi: 10.1007/s13555-020-00377-9. [Epub ahead of print]
https://doi.org/10.1007/s13555-020-00377-9

Psoriasis and psoriatic arthritis: how to manage immunosuppressants in COVID-19 days.
Coletto LA, Favalli EG, Caporali R.
Dermatol Ther. 2020 Apr 14:e13415. doi: 10.1111/dth.13415. [Epub ahead of print] No abstract available.
https://doi.org/10.1111/dth.13415

SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.
Messina F, Piaserico S.
J Eur Acad Dermatol Venereol. 2020 Apr 15. doi: 10.1111/jdv.16468. [Epub ahead of print]
https://doi.org/10.1111/jdv.16468

Psoriasis health care in the time of the coronavirus pandemic: insights from dedicated centers in sardinia (Italy).
Atzori L, Mugheddu C, Addis G, Sanna S, Satta R, Ferreli C, Atzori MG, Montesu MA, Rongioletti F.
J Eur Acad Dermatol Venereol. 2020 Apr 15. doi: 10.1111/jdv.16473. [Epub ahead of print]
https://doi.org/10.1111/jdv.16473

Managing cutaneous immune-mediated diseases during the COVID-19 pandemic.
Torres T, Puig L.
Am J Clin Dermatol. 2020 Apr 10. doi: 10.1007/s40257-020-00514-2. [Epub ahead of print]
https://doi.org/10.1007/s40257-020-00514-2

SECURE-Psoriasis: A de-identified registry of psoriasis patients diagnosed with COVID-19.
Balogh EA, Heron C, Feldman SR, Huang WW.
J Dermatolog Treat. 2020 Apr 8:1-2. doi: 10.1080/09546634.2020.1753996. [Epub ahead of print] No abstract available.
https://doi.org/10.1080/09546634.2020.1753996

A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?
Kutlu Ö, Metin A.
Dermatol Ther. 2020 Apr 7:e13383. doi: 10.1111/dth.13383. [Epub ahead of print] No abstract available.
https://doi.org/10.1111/dth.13383

The COVID-19 outbreak and rheumatologic skin diseases.
Arora G, Kassir M, Jafferany M, Galadari H, Lotti T, Satolli F, Sadoughifar R, Sitkowska Z, Goldust M.
Dermatol Ther. 2020 Mar 31:e13357. doi: 10.1111/dth.13357. [Epub ahead of print] No abstract available.
https://doi.org/10.1111/dth.13357

Antipsoriatic treatments during COVID-19 outbreak.
Di Lernia V.
Dermatol Ther. 2020 Mar 29:e13345. doi: 10.1111/dth.13345. [Epub ahead of print] No abstract available.
https://doi.org/10.1111/dth.13345 

 

Atopic dermatitis

 

Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries.
Gadarowski MB, Balogh EA, Bashyam AM, Feldman SR.
J Dermatolog Treat. 2020 Aug 8:1-17. doi: 10.1080/09546634.2020.1808154. Online ahead of print. Review.
https://doi.org/10.1080/09546634.2020.1808154Biologic drugs during COVID-19 outbreak.
Montesu MA, Biondi G, Sotgiu G, Sucato F, Satta R.
Int J Dermatol. 2020 Aug 6. doi: 10.1111/ijd.15088. Online ahead of print. Cohort study.
https://doi.org/10.1111/ijd.15088

COVID-19 and immunosuppressive therapy in dermatology.
Schwartz RA, Pradhan S, Murrell DF, Jafferany M, Olisova OY, Lomonosov KM, Lotti T, Goldust M.
Dermatol Ther. 2020 Aug 7:e14140. doi: 10.1111/dth.14140. Online ahead of print. Review / recommendations.
https://doi.org/10.1111/dth.14140

Impact of the COVID-19 pandemic on chronic inflammatory dermatoses: Mixed messages regarding the dermatologist's point of view and the patient's concerns.
Fougerousse AC, Maccari F, Reguiai Z, Begon E, Pallure V, Taïeb C, Girard C, Mery-Bossard L.
Acta Derm Venereol. 2020 Jul 31. doi: 10.2340/00015555-3610. Online ahead of print. Commentary.
https://doi.org/10.2340/00015555-3610

COVID-19 and implications for dermatological and allergological diseases.
Buhl T, Beissert S, Gaffal E, Goebeler M, Hertl M, Mauch C, Reich K, Schmidt E, Schön MP, Sticherling M, Sunderkötter C, Traidl-Hoffmann C, Werfel T, Wilsman-Theis D, Worm M.
J Dtsch Dermatol Ges. 2020 Jul 27. doi: 10.1111/ddg.14195. Online ahead of print. Review.
https://doi.org/10.1111/ddg.14195

Atopy is predictive of a decreased need for hospitalization for COVID-19.
Keswani A, Dhana K, Rosenthal JA, Moore D, Mahdavinia M.
Ann Allergy Asthma Immunol. 2020 Jul 18:S1081-1206(20)30489-0. doi: 10.1016/j.anai.2020.07.012. Online ahead of print. Cohort study.
https://doi.org/10.1016/j.anai.2020.07.012

Risk of COVID-19 in dermatologic patients on long-term immunomodulatory therapy.
Holcomb ZE, Santillan MR, Morss-Walton PC, Salian P, Her MJ, Giannotti NM, Kimball AB, Porter ML.
J Am Acad Dermatol. 2020 Jul 1. pii: S0190-9622(20)32099-5. doi: 10.1016/j.jaad.2020.06.999. [Epub ahead of print] No abstract available. Retrospective cross-sectional study.
https://doi.org/10.1016/j.jaad.2020.06.999

Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic.
Kearns DG, Uppal S, Chat VS, Wu JJ.
J Am Acad Dermatol. 2020 Jun 10. pii: S0190-9622(20)31075-6. doi: 10.1016/j.jaad.2020.06.015. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1016/j.jaad.2020.06.015

Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status.
Du H, Dong X, Zhang JJ, Cao YY, Akdis M, Huang PQ, Chen HW, Li Y, Liu GH, Akdis CA, Lu XX, Gao YD.
Allergy. 2020 Jun 10. doi: 10.1111/all.14452. [Epub ahead of print]. Cross-sectional study.
https://doi.org/10.1111/all.14452

Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: a single-center real-life experience.
Rossi M, Rovati C, Arisi M, Soglia S, Calzavara-Pinton P.
Dermatol Ther. 2020 Jun 4:e13765. doi: 10.1111/dth.13765. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1111/dth.13765

Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.
Ricardo JW, Lipner SR.
Dermatol Ther. 2020 May 27. doi: 10.1111/dth.13687. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13687

COVID-19, quarantine, and atopic dermatitis.
Patruno C, Nisticò SP, Fabbrocini G, Napolitano M.
Med Hypotheses. 2020 May 19;143:109852. doi: 10.1016/j.mehy.2020.109852. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1016/j.mehy.2020.109852

Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19.
Galimberti F, McBride J, Cronin M, Li Y, Fox J, Abrouk M, Herbst A, Kirsner RS.
Clin Dermatol. 2020 May 14. doi: 10.1016/j.clindermatol.2020.05.003. [Epub ahead of print]. Review / recommendations.
https://doi.org/10.1016/j.clindermatol.2020.05.003

Safety of dupilumab in atopic patients during COVID-19 outbreak.
Napolitano M, Patruno C, Ruggiero A, Nocerino M, Fabbrocini G.
J Dermatolog Treat. 2020 May 18:1-5. doi: 10.1080/09546634.2020.1771257. [Epub ahead of print] No abstract available. Survey / cross-sectional study.
https://doi.org/10.1080/09546634.2020.1771257

Optimizing care for atopic dermatitis patients during COVID-19 pandemic.
Shah M, Sachdeva M, Alavi A, Shi VY, Hsiao JL.
J Am Acad Dermatol. 2020 May 13. doi: 10.1016/j.jaad.2020.05.027. [Epub ahead of print] No abstract available. Commentary / management recommendations.
https://doi.org/10.1016/j.jaad.2020.05.027

SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab.
Caroppo F, Biolo G, Belloni Fortina A.
J Eur Acad Dermatol Venereol. 2020 May 9. doi: 10.1111/jdv.16619. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16619

Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?
Kutlu Ö, Metin A.
Dermatol Ther. 2020 May 5:e13509. doi: 10.1111/dth.13509. [Epub ahead of print]. Case series.
https://doi.org/10.1111/dth.13509

Dupilumab and COVID-19: what should we expect?
Patruno C, Stingeni L, Fabbrocini G, Hansel K, Napolitano M.
Dermatol Ther. 2020 May 2. doi: 10.1111/dth.13502. [Epub ahead of print]. Commentary.
https://doi.org/10.1111/dth.13502

Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.
Mahil SK, Yiu ZZN, Mason KJ, Dand N, Coker B, Wall D, Fletcher G, Bosma A, Capon F, Iversen L, Langan SM, Di Meglio P, Musters A, Prieto-Merino D, Tsakok T, Warren RB, Flohr C, Spuls P, Griffiths CEM, Barker J, Irvine AD, Smith CH; Secure-AD, PsoPROTECT study groups.
Br J Dermatol. 2020 Apr 29. doi: 10.1111/bjd.19161. [Epub ahead of print]. Letter/commentary.
https://doi.org/10.1111/bjd.19161

No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.
Carugno A, Raponi F, Locatelli AG, Vezzoli P, Gambini DM, Di Mercurio M, Robustelli Test E, Sena P.
J Eur Acad Dermatol Venereol. 2020 Apr 27. doi: 10.1111/jdv.16552. [Epub ahead of print]. Case series.
https://doi.org/10.1111/jdv.16552

Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.
Ferrucci S, Romagnuolo M, Angileri L, Berti E, Tavecchio S.
J Eur Acad Dermatol Venereol. 2020 Apr 24. doi: 10.1111/jdv.16527. [Epub ahead of print]
https://doi.org/10.1111/jdv.16527

 

Skin cancers

Reduction in skin cancer diagnoses in the UK during COVID-19 pandemic.
Andrew TW, Alrawi M, Lovat P.
Clin Exp Dermatol. 2020 Aug 5. doi: 10.1111/ced.14411. Online ahead of print. Research study / audit.
https://doi.org/10.1111/ced.14411

COVID-19 board: Our multidisciplinary cutaneous oncology tumor board during the coronavirus-19 pandemic.
Chow M, Jiang SIB.
Dermatol Surg. 2020 Jul 31. doi: 10.1097/DSS.0000000000002568. Online ahead of print. Report / commentary.
https://doi.org/10.1097/dss.0000000000002568

Melanoma and COVID-19: A narrative review focused on treatment.
Elmas ÖF, Demirbaş A, Düzayak S, Atasoy M, Türsen Ü, Lotti T.
Dermatol Ther. 2020 Jul 31. doi: 10.1111/dth.14101. Online ahead of print. Review.
https://doi.org/10.1111/dth.14101

COVID-19 and skin cancer management: French nation-wide questionnaire survey from real-life practice.
Nardin C, Puzenat E, Dalac S, Maubec E, Aubin F; GCC.
J Dermatolog Treat. 2020 Jul 29:1-6. doi: 10.1080/09546634.2020.1801972. Online ahead of print. Survey.
https://doi.org/10.1080/09546634.2020.1801972

COVID-19 and implications for dermatological and allergological diseases.
Buhl T, Beissert S, Gaffal E, Goebeler M, Hertl M, Mauch C, Reich K, Schmidt E, Schön MP, Sticherling M, Sunderkötter C, Traidl-Hoffmann C, Werfel T, Wilsman-Theis D, Worm M.
J Dtsch Dermatol Ges. 2020 Jul 27. doi: 10.1111/ddg.14195. Online ahead of print. Review.
https://doi.org/10.1111/ddg.14195

Surgical delay and mortality for primary cutaneous melanoma.
Guhan S, Boland G, Tanabe K, Lin W, Reddy B, Hawryluk EB, Sober AJ, Tsao H.
J Am Acad Dermatol. 2020 Jul 22:S0190-9622(20)32279-9. doi: 10.1016/j.jaad.2020.07.078. Online ahead of print. Review.
https://doi.org/10.1016/j.jaad.2020.07.078

A significant reduction in the diagnosis of melanoma during the Covid-19 lockdown in a third level center in the north of Italy.
Barruscotti S, Giorgini C, Brazzelli V, Vassallo C, Michelerio A, Klersy C, Chiellino S, Tomasini CF.
Dermatol Ther. 2020 Jul 26. doi: 10.1111/dth.14074. Online ahead of print. Retrospective case review / audit.
https://doi.org/10.1111/dth.14074

Melanoma: A silver lining in the black cloud of Covid-19.
Kassir M, Podder I, Olisova OY, Lomonosov KM, Lotti T, Goldust M.
Dermatol Ther. 2020 Jul 26. doi: 10.1111/dth.14070. Online ahead of print. Commentary.
https://doi.org/10.1111/dth.14070

Comment on "Rescheduling of clinical activities and teleconsulting for public dermatology. Two prompt answers to COVID-19 emergency".
De Simone P, Iorio A, Ardigò M, Silipo V, Ferrari A, Morrone A, Frascione P.
Int J Dermatol. 2020 Jul 25. doi: 10.1111/ijd.15026. Online ahead of print. Commentary.
https://doi.org/10.1111/ijd.15026

Skin cancer and COVID-19.
Goldust M, Agarwal K, Podder I, Navarini AA.
Dermatol Ther. 2020 Jul 23:e14050. doi: 10.1111/dth.14050. Online ahead of print. Commentary.
https://doi.org/10.1111/dth.14050

Immune checkpoint inhibition in the era of COVID-19.
Kurzhals J, Terheyden P, Langan EA.
Clin Exp Dermatol. 2020 Jul 8. doi: 10.1111/ced.14370. [Epub ahead of print]. Review.
https://doi.org/10.1111/ced.14370

On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19.
Gambichler T, Reuther J, Scheel CH, Becker JC.
J Immunother Cancer. 2020 Jul;8(2). pii: e001145. doi: 10.1136/jitc-2020-001145. Review.
https://pmlegacy.ncbi.nlm.nih.gov/pubmed/32611687

Management of patients with melanoma and non-melanoma skin cancers in the coronavirus disease 2019 era.
Conforti C, di Meo N, Giuffrida R, Zalaudek I.
Chin Med J (Engl). 2020 Jun 9. doi: 10.1097/CM9.0000000000000930. [Epub ahead of print] No abstract available. Editorial.
https://doi.org/10.1097/CM9.0000000000000930

Estimated effect of COVID-19 lockdown on skin tumor size and survival: An exponential growth model.
Tejera-Vaquerizo A, Cañueto J, Toll A, Santos-Juanes J, Jaka A, Ferrandiz-Pulido C, Sanmartín O, Ribero S, Moreno-Ramírez D, Almazán F, Fuente MJ, Podlipnik S, Nagore E.
Actas Dermosifiliogr. 2020 May 11. pii: S0001-7310(20)30142-3. doi: 10.1016/j.ad.2020.05.001. [Epub ahead of print] Review. English, Spanish. Observational cohort study & model.
https://doi.org/10.1016/j.ad.2020.05.001

Severity and risk of COVID-19 in cancer patients: An evidence based learning.
Sharma A, Malviya R, Kumar V, Gupta R, Awasthi R.
Dermatol Ther. 2020 Jun 8:e13778. doi: 10.1111/dth.13778. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13778

Safe distance, safe patients! Therapeutic management of oncological patients affected by cutaneous and mucosal adverse events during the COVID-19 pandemic: an Italian experience.
Cinelli E, Fabbrocini G, Fattore D, Marasca C, Damiani G, Annunziata MC.
Support Care Cancer. 2020 Jun 8. doi: 10.1007/s00520-020-05563-1. [Epub ahead of print]. Survey / cross-sectional study.
https://doi.org/10.1007/s00520-020-05563-1

Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic.
Earnshaw CH, Hunter HJA, McMullen E, Griffiths CEM, Warren RB.
Br J Dermatol. 2020 Jun 4. doi: 10.1111/bjd.19267. [Epub ahead of print]. Research study / audit.
https://doi.org/10.1111/bjd.19267

Melanoma defies 'lockdown': ongoing detection during Covid-19 in central London.
Schauer AA, Kulakov EL, Martyn-Simmons CL, Bunker CB, Edmonds E.
Clin Exp Dermatol. 2020 Jun 5. doi: 10.1111/ced.14324. [Epub ahead of print]. Case series / audit.
https://doi.org/10.1111/ced.14324

Increasing melanoma awareness amongst health and social care professionals in secondary care in an era of reduced skin cancer referrals.
Quinlan C, Gill R, Murphy M.
Clin Exp Dermatol. 2020 Jun 2. doi: 10.1111/ced.14323. [Epub ahead of print]. Survey.
https://doi.org/10.1111/ced.14323

Virtual melanoma checks during a pandemic.
Janda M, Swetter SM, Horsham C, Soyer HP.
Br J Dermatol. 2020 May 29. doi: 10.1111/bjd.19255. [Epub ahead of print]. Commentary / recommendations.
https://doi.org/10.1111/bjd.19255

Melanoma screening days during the coronavirus disease 2019 (COVID-19) pandemic: Strategies to adopt.
Villani A, Fabbrocini G, Costa C, Scalvenzi M.
Dermatol Ther (Heidelb). 2020 May 28. doi: 10.1007/s13555-020-00402-x. [Epub ahead of print]. Commentary / recommendations.
https://doi.org/10.1007/s13555-020-00402-x

Hypofractionated radiotherapy in patients with non-melanoma skin cancer in the post COVID-19 era: Time to reconsider its role for most patients.
Veness M.
J Med Imaging Radiat Oncol. 2020 May 27. doi: 10.1111/1754-9485.13070. [Epub ahead of print]. Commentary.
https://doi.org/10.1111/1754-9485.13070

COVID-19 in a melanoma patient under treatment with checkpoint-inhibition.
Schmidle P, Biedermann T, Posch C.
J Eur Acad Dermatol Venereol. 2020 May 26. doi: 10.1111/jdv.16661. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16661

COVID-19 and dermatology: A comprehensive guide for dermatologists.
Fahmy DH, El-Amawy HS, El-Samongy MA, Foud AA, Soliman SH, El-Kady A, Farnetani F, Conti A, Zoeir A, Eissa A, Eissa R, Puliatti S, Sighinolfi MC, Rocco B, Pellacani G.
J Eur Acad Dermatol Venereol. 2020 May 19. doi: 10.1111/jdv.16545. [Epub ahead of print]. Review / commentary.
https://doi.org/10.1111/jdv.16545

Metastatic melanoma treatment with check point inhibitors in the COVID-19 era: experience from an Italian Skin Cancer Unit.
Quaglino P, Fava P, Brizio M, Marra E, Rubatto M, Agostini A, Tonella L, Ribero S, Fierro MT.
J Eur Acad Dermatol Venereol. 2020 May 19. doi: 10.1111/jdv.16586. [Epub ahead of print]. Commentary.
https://doi.org/10.1111/jdv.16586

Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.
Yekedüz E, Dursun B, Aydın GÇ, Yazgan SC, Öztürk HH, Azap A, Utkan G, Ürün Y.
J Oncol Pharm Pract. 2020 May 19:1078155220924084. doi: 10.1177/1078155220924084. [Epub ahead of print]. Case report.
https://doi.org/10.1177/1078155220924084

Radiotherapy and systemic treatment for non-melanoma skin cancer in the COVID-19 pandemic.
Rembielak A, Sykes AJ, Fife K, Challapalli A, Nobes JP.
Clin Oncol (R Coll Radiol). 2020 May 7. pii: S0936-6555(20)30194-1. doi: 10.1016/j.clon.2020.04.014. [Epub ahead of print] No abstract available. Editorial / recommendations.
https://doi.org/10.1016/j.clon.2020.04.014

Considerations for management of longitudinal melanonychia during the COVID-19 pandemic: An international perspective.
Lipner SR, Iorizzo M, Jellinek N, Piraccini BM, Scher RK.
J Am Acad Dermatol. 2020 May 13. doi: 10.1016/j.jaad.2020.05.028. [Epub ahead of print] No abstract available. Commentary / management recommendations.
https://doi.org/10.1016/j.jaad.2020.05.028

Perspectives on the recommendations for skin cancer management during the COVID-19 pandemic.
Geskin LJ, Trager MH, Aasi SZ, Bickers DR, Carvajal RD, Nghiem P, Taback B, Zeitouni NC, Samie FH.
J Am Acad Dermatol. 2020 May 6. pii: S0190-9622(20)30821-5. doi: 10.1016/j.jaad.2020.05.002. [Epub ahead of print] No abstract available. Editorial / commentary.
https://doi.org/10.1016/j.jaad.2020.05.002

Struggling with COVID: Every cancer patient is unique, and needs their own plan.
Alam M.
J Am Acad Dermatol. 2020 May 6. pii: S0190-9622(20)30820-3. doi: 10.1016/j.jaad.2020.04.166. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1016/j.jaad.2020.04.166

Covid infection and sentinel lymph node procedure for melanoma: management in a dermo-oncology centre in a high-risk pandemic area.
Caliendo V, Picciotto F, Quaglino P, Ribero S.
Dermatol Ther. 2020 May 8. doi: 10.1111/dth.13536. [Epub ahead of print] No abstract available. Report / commentary.
https://doi.org/10.1111/dth.13536

Estimated effect of COVID-19 lockdown on melanoma thickness and prognosis: a rate of growth model.
Tejera-Vaquerizo A, Nagore E.
J Eur Acad Dermatol Venereol. 2020 May 2. doi: 10.1111/jdv.16555. [Epub ahead of print]. Letter / model.
https://doi.org/10.1111/jdv.16555

Skin cancer plastic surgery during the COVID-19 pandemic.
Gentileschi S, Caretto AA, Tagliaferri L, Salgarello M, Peris K.
Eur J Surg Oncol. 2020 May 1. pii: S0748-7983(20)30445-5. doi: 10.1016/j.ejso.2020.04.048. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1016/j.ejso.2020.04.048

The danger of neglecting melanoma during the COVID-19 pandemic.
Gomolin T, Cline A, Handler MZ.
J Dermatolog Treat. 2020 Apr 29:1-8. doi: 10.1080/09546634.2020.1762844. [Epub ahead of print]. Commentary.
https://doi.org/10.1080/09546634.2020.1762844

Skin cancer triage and management during COVID-19 pandemic.
Tagliaferri L, Di Stefani A, Schinzari G, Fionda B, Rossi E, Del Regno L, Gentileschi S, Federico F, Valentini V, Tortora G, Peris K; Gemelli Skin-Cancer Multidisciplianry Tumour Board (S-MDTB).
J Eur Acad Dermatol Venereol. 2020 Apr 25. doi: 10.1111/jdv.16529. [Epub ahead of print]. Commentary.
https://doi.org/10.1111/jdv.16529

Patients with advanced basal cell carcinomas in treatment with sonic hedgehog inhibitors during the coronavirus disease 2019 (COVID-19) period: Management and adherence to treatment.
Villani A, Fabbrocini G, Costa C, Scalvenzi M.
J Am Acad Dermatol. 2020 Mar 31. pii: S0190-9622(20)30479-5. doi: 10.1016/j.jaad.2020.03.057. [Epub ahead of print] No abstract available.
https://doi.org/10.1016/j.jaad.2020.03.057  

Management of advanced melanoma in the COVID-19 era.
Conforti C, Giuffrida R, Di Meo N, Zalaudek I.
Dermatol Ther. 2020 Apr 22:eacronym. doi: 10.1111/dth.13444. [Epub ahead of print] No abstract available.
https://doi.org/10.1111/dth.13444

 

Hidradenitis suppurativa

Biologic drugs during COVID-19 outbreak.
Montesu MA, Biondi G, Sotgiu G, Sucato F, Satta R.
Int J Dermatol. 2020 Aug 6. doi: 10.1111/ijd.15088. Online ahead of print. Cohort study.
https://doi.org/10.1111/ijd.15088

Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic.
Kearns DG, Chat VS, Uppal S, Wu JJ.
J Am Acad Dermatol. 2020 Jul 28:S0190-9622(20)32287-8. doi: 10.1016/j.jaad.2020.07.086. Online ahead of print. Trial analysis / commentary.
https://doi.org/10.1016/j.jaad.2020.07.086

Treating hidradenitis suppurativa during the COVID-19 pandemic: teledermatology exams of sensitive body areas.
Okeke CAV, Shipman WD, Perry JD, Kerns ML, Okoye GA, Byrd AS.
J Dermatolog Treat. 2020 Jul 9:1-2. doi: 10.1080/09546634.2020.1781042. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1080/09546634.2020.1781042

Risk of COVID-19 in dermatologic patients on long-term immunomodulatory therapy.
Holcomb ZE, Santillan MR, Morss-Walton PC, Salian P, Her MJ, Giannotti NM, Kimball AB, Porter ML.
J Am Acad Dermatol. 2020 Jul 1. pii: S0190-9622(20)32099-5. doi: 10.1016/j.jaad.2020.06.999. [Epub ahead of print] No abstract available. Retrospective cross-sectional study.
https://doi.org/10.1016/j.jaad.2020.06.999

Global Hidradenitis Suppurativa COVID-19 Registry: A registry to inform data-driven management practices.
Naik HB, Alhusayen R, Frew J, Guilbault S, Ingram JR, Lowes MA, Marzano AV, Paul M, Villumsen B, Yannuzzi CA.
Br J Dermatol. 2020 Jun 29. doi: 10.1111/bjd.19345. [Epub ahead of print]. Research letter.
https://doi.org/10.1111/bjd.19345

Experience in patients with hidradenitis suppurativa and COVID-19 symptoms.
Galán Sánchez JL, San Nicasio CS, Olivares MG, Martín CG, Madueño KD, Martín Díaz MÁ, Tarjuelo DV, Dobao PC.
J Am Acad Dermatol. 2020 Jun 27. pii: S0190-9622(20)32086-7. doi: 10.1016/j.jaad.2020.06.986. [Epub ahead of print]. Case series.
https://doi.org/10.1016/j.jaad.2020.06.986

Remote management of hidradenitis suppurativa in a pandemic era of COVID-19.
Kang NC, Hsiao J, Shi V, Naik HB, Lowes MA, Alavi A.
Int J Dermatol. 2020 Jun 23. doi: 10.1111/ijd.15022. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1111/ijd.15022

Management of patients with hidradenitis suppurativa during the COVID-19 pandemic.
Montero-Vilchez T, Martinez-Lopez A, Salvador-Rodriguez L, Molina-Leyva A, Arias-Santiago S.
Dermatol Ther. 2020 Jun 19:e13875. doi: 10.1111/dth.13875. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13875

Moderate to severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak.
Giulia R, Alice R, Teresa FM, Paolo D, Simone R.
Dermatol Ther. 2020 May 24. doi: 10.1111/dth.13680. [Epub ahead of print] No abstract available. Retrospective cohort study.
https://doi.org/10.1111/dth.13680

Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?
Rosi E, Pimpinelli N, Prignano F.
J Dermatolog Treat. 2020 May 20:1-4. doi: 10.1080/09546634.2020.1771256. [Epub ahead of print] No abstract available. Letter / commentary.
https://doi.org/10.1080/09546634.2020.1771256

Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral centre of Southern Italy.
Marasca C, Ruggiero A, Megna M, Annunziata MC, Fabbrocini G.
J Dermatolog Treat. 2020 May 13:1-3. doi: 10.1080/09546634.2020.1769828. [Epub ahead of print] No abstract available.
https://doi.org/10.1080/09546634.2020.1769828

Exploring the risk of severe COVID-19 infection in hidradenitis suppurativa patients.
Seltzer JA, Okeke CAV, Perry JD, Shipman WD, Okoye GA, Byrd AS.
J Am Acad Dermatol. 2020 May 7. pii: S0190-9622(20)30839-2. doi: 10.1016/j.jaad.2020.05.012. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1016/j.jaad.2020.05.012

Dermatology patients' knowledge and concerns regarding their immunomodulatory medication during the COVID-19 pandemic.
Keeling E, Daly S, McKenna DB.
Dermatol Ther. 2020 May 1:e13488. doi: 10.1111/dth.13488. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1111/dth.13488

Hidradenitis suppurativa: the importance of virtual outpatient care during COVID-19 pandemic.
Shah M, Naik HB, Alhusayen R.
J Am Acad Dermatol. 2020 Apr 30. pii: S0190-9622(20)30763-5. doi: 10.1016/j.jaad.2020.04.142. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1016/j.jaad.2020.04.142

The role of virtual support groups for patients with hidradenitis suppurativa during the COVID-19 pandemic.
Stout M.
Int J Womens Dermatol. 2020 Apr 29. doi: 10.1016/j.ijwd.2020.04.009. [Epub ahead of print] No abstract available. Report / commentary.
https://doi.org/10.1016/j.ijwd.2020.04.009

Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations.
Blaszczak A, Trinidad JCL, Cartron AM.
J Am Acad Dermatol. 2020 Apr 10. pii: S0190-9622(20)30606-X. doi: 10.1016/j.jaad.2020.04.030. [Epub ahead of print] No abstract available.
https://doi.org/10.1016/j.jaad.2020.04.030

Managing cutaneous immune-mediated diseases during the COVID-19 pandemic.
Torres T, Puig L.
Am J Clin Dermatol. 2020 Apr 10. doi: 10.1007/s40257-020-00514-2. [Epub ahead of print]
https://doi.org/10.1007/s40257-020-00514-2

 

Bullous diseases

COVID-19 and immunosuppressive therapy in dermatology.
Schwartz RA, Pradhan S, Murrell DF, Jafferany M, Olisova OY, Lomonosov KM, Lotti T, Goldust M.
Dermatol Ther. 2020 Aug 7:e14140. doi: 10.1111/dth.14140. Online ahead of print. Review / recommendations.
https://doi.org/10.1111/dth.14140

Management of patients with pemphigus vulgaris during the COVID-19 pandemic: Experience of a second level dermatology center.
Diotallevi F, Simonetti O, Radi G, Campanati A, Brisigotti V, Tagliati C, Rizzetto G, Martina E, Offidani A.
Australas J Dermatol. 2020 Aug 5. doi: 10.1111/ajd.13414. Online ahead of print. Report / audit.
https://doi.org/10.1111/ajd.13414

Treatment of severe pemphigus vulgaris during COVID-19 pandemic.
Pathania YS, Bhardwaj A.
J Dermatolog Treat. 2020 Jul 29:1-4. doi: 10.1080/09546634.2020.1801971. Online ahead of print. Commentary / recommendations.
https://doi.org/10.1080/09546634.2020.1801971

COVID-19 and implications for dermatological and allergological diseases.
Buhl T, Beissert S, Gaffal E, Goebeler M, Hertl M, Mauch C, Reich K, Schmidt E, Schön MP, Sticherling M, Sunderkötter C, Traidl-Hoffmann C, Werfel T, Wilsman-Theis D, Worm M.
J Dtsch Dermatol Ges. 2020 Jul 27. doi: 10.1111/ddg.14195. Online ahead of print. Review.
https://doi.org/10.1111/ddg.14195

Treatment concerns for bullous pemphigoid in the COVID-19 pandemic era.
Azimi SZ, Firooz A, Murrell DF, Daneshpazhooh M.
Dermatol Ther. 2020 Jul 4:e13956. doi: 10.1111/dth.13956. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13956

Risk of COVID-19 in dermatologic patients on long-term immunomodulatory therapy.
Holcomb ZE, Santillan MR, Morss-Walton PC, Salian P, Her MJ, Giannotti NM, Kimball AB, Porter ML.
J Am Acad Dermatol. 2020 Jul 1. pii: S0190-9622(20)32099-5. doi: 10.1016/j.jaad.2020.06.999. [Epub ahead of print] No abstract available. Retrospective cross-sectional study.
https://doi.org/10.1016/j.jaad.2020.06.999

COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: A tele-medicine experience.
Shahidi-Dadras M, Abdollahimajd F, Ohadi L, Tabary M, Araghi F, Mozafari N, Toosi P, Dadkhahfar S.
J Dermatolog Treat. 2020 Jun 27:1-7. doi: 10.1080/09546634.2020.1789041. [Epub ahead of print]. Cross-sectional study.
https://doi.org/10.1080/09546634.2020.1789041

Patients with specific skin disorders who are affected by COVID-19: what do experiences say about management strategies? : A systematic review.
Najar Nobar N, Goodarzi A.
Dermatol Ther. 2020 Jun 18:e13867. doi: 10.1111/dth.13867. [Epub ahead of print]. Systematic review.
https://doi.org/10.1111/dth.13867

Bullous skin disease patients in a high-epidemic COVID-19 area, Bergamo, Italy.
Carugno A, Sena P, Raponi F, Robustelli Test E, Vezzoli P.
Br J Dermatol. 2020 Jun 1. doi: 10.1111/bjd.19266. [Epub ahead of print]. Case series.
https://doi.org/10.1111/bjd.19266

Patients with bullous disorders during COVID-19 period: management and adherence to treatment.
De Fata Salvatores G, Villani A, Fabbrocini G, Di Guida A.
Dermatol Ther. 2020 May 26:e13697. doi: 10.1111/dth.13697. [Epub ahead of print] No abstract available. Report / audit.
https://doi.org/10.1111/dth.13697

Management of pemphigus in COVID-19 pandemic era; a review article.
Abdollahimajd F, Shahidi-Dadras M, M Robati R, Dadkhahfar S.
Arch Acad Emerg Med . 2020 Apr 18;8(1):e51. eCollection 2020. Review.
http://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/663/789

Management strategies of autoimmune bullous diseases during the outbreak of 2019 novel coronavirus disease (COVID-19).
Chen P, Zhang G, Zhan Y.
J Dermatolog Treat. 2020 May 18:1-7. doi: 10.1080/09546634.2020.1771261. [Epub ahead of print]. Recommendations / commentary.
https://doi.org/10.1080/09546634.2020.1771261

Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case-report.
Daneshpazhooh M, Soori T, Isazade A, Noormohammadpour P.
J Dermatolog Treat. 2020 May 2:1-6. doi: 10.1080/09546634.2020.1764472. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1080/09546634.2020.1764472

Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus.
Balestri R, Rech G, Girardelli CR.
J Eur Acad Dermatol Venereol. 2020 May 2. doi: 10.1111/jdv.16578. [Epub ahead of print]. Case report / commentary.
https://doi.org/10.1111/jdv.16578

Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?
Di Altobrando A, Patrizi A, Bardazzi F.
J Eur Acad Dermatol Venereol. 2020 Apr 17. doi: 10.1111/jdv.16491. [Epub ahead of print]
https://doi.org/10.1111/jdv.16491

Treatment considerations for patients with pemphigus during the COVID-19 pandemic.
Shakshouk H, Daneshpazhooh M, Murrell DF, Lehman JS.
J Am Acad Dermatol. 2020 Apr 10. pii: S0190-9622(20)30544-2. doi: 10.1016/j.jaad.2020.04.005. [Epub ahead of print] No abstract available.
https://doi.org/10.1016/j.jaad.2020.04.005

 

Paediatric

Young children presenting with fever and rash in the midst of SARS-CoV-2 outbreak in New York.
Wolfe DM, Nassar GN, Divya K, Krilov LR, Noor A.
Clin Pediatr (Phila). 2020 Jul 7:9922820941631. doi: 10.1177/0009922820941631. [Epub ahead of print] No abstract available. Case reports.
https://doi.org/10.1177/0009922820941631

At home dose escalation of propranolol for infantile hemangiomas during the COVID-19 pandemic.
Bassi A, Azzarelli A, Vaccaro A, Mazzatenta C.
Dermatol Ther. 2020 Jul 7:e13977. doi: 10.1111/dth.13977. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1111/dth.13977

Special dermatological presentation of paediatric multisystem inflammatory syndrome related to COVID-19: erythema multiforme.
Bapst T, Romano F, Müller M, Rohr M.
BMJ Case Rep. 2020 Jun 29;13(6). pii: e236986. doi: 10.1136/bcr-2020-236986. No abstract available. Case report.
https://doi.org/10.1136/bcr-2020-236986

Introductory histopathologic findings may shed light on COVID19 pediatric hyperinflammatory shock syndrome.
Schnapp A, Abulhija H, Maly A, Armoni-Weiss G, Levin Y, Faitatziadou SM, Molho-Pessach V.
J Eur Acad Dermatol Venereol. 2020 Jun 13. doi: 10.1111/jdv.16749. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16749

Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status.
Du H, Dong X, Zhang JJ, Cao YY, Akdis M, Huang PQ, Chen HW, Li Y, Liu GH, Akdis CA, Lu XX, Gao YD.
Allergy. 2020 Jun 10. doi: 10.1111/all.14452. [Epub ahead of print]. Cross-sectional study.
https://doi.org/10.1111/all.14452

Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated With SARS-CoV-2.
Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, Ramnarayan P, Fraisse A, Miller O, Davies P, Kucera F, Brierley J, McDougall M, Carter M, Tremoulet A, Shimizu C, Herberg J, Burns JC, Lyall H, Levin M; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia.
JAMA. 2020 Jun 8. doi: 10.1001/jama.2020.10369. [Epub ahead of print]. Case series.
https://doi.org/10.1001/jama.2020.10369

Global coronavirus pandemic (SARS CoV-2): Past, present, and future of pediatric dermatology.
Simonetti O, Diotallevi F, Campanati A, Brisigotti V, Radi G, Molinelli E, Bobyr I, Martina E, Paolinelli M, Sapigni C, Offidani A.
Dermatol Ther. 2020 Jun 4:e13767. doi: 10.1111/dth.13767. [Epub ahead of print]. Report / audit.
https://doi.org/10.1111/dth.13767

COVID-19 and ectodermal dysplasias. Recommendations are necessary.
Callea M, Willoughby CE, Perry D, Holzer U, Fedele G, Cárdenas Tadich A, Cammarata-Scalisi F.
Dermatol Ther. 2020 May 30:e13702. doi: 10.1111/dth.13702. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13702

Multisystem Inflammatory Syndrome in Children during the COVID-19 pandemic: a case series.
Chiotos K, Bassiri H, Behrens EM, Blatz AM, Chang J, Diorio C, Fitzgerald JC, Topjian A, John ARO.
J Pediatric Infect Dis Soc. 2020 May 28. pii: piaa069. doi: 10.1093/jpids/piaa069. [Epub ahead of print]. Case series.
https://doi.org/10.1093/jpids/piaa069

Management of infantile hemangiomas during the COVID pandemic.
Frieden IJ, Püttgen KB, Drolet BA, Garzon MC, Chamlin SL, Pope E, Mancini AJ, Lauren CT, Mathes EF, Siegel DH, Gupta D, Haggstrom AN, Tollefson MM, Baselga E, Morel KD, Shah SD, Holland KE, Adams DM, Horii KA, Newell BD, Powell J, McCuaig CC, Nopper AJ, Metry DW, Maguiness S; Hemangioma Investigator Group.
Pediatr Dermatol. 2020 Apr 16. doi: 10.1111/pde.14196. [Epub ahead of print]
https://doi.org/10.1111/pde.14196

COVID-19 in the pediatric population.
Abdelmaksoud A, Kroumpouzos G, Jafferany M, Lotti T, Sadoughifar R, Goldust M.
Dermatol Ther. 2020 Mar 27:e13339. doi: 10.1111/dth.13339. [Epub ahead of print] No abstract available.
https://doi.org/10.1111/dth.13339

Infants born to mothers with a new coronavirus (COVID-19).
Chen Y, Peng H, Wang L, Zhao Y, Zeng L, Gao H, Liu Y.
Front Pediatr. 2020 Mar 16;8:104. doi: 10.3389/fped.2020.00104. eCollection 2020.
https://doi.org/10.3389/fped.2020.00104
# Symptoms included rashes of unknown aetiology at birth

 

Other conditions and groups

Intralesional antigen immunotherapy for warts in the era of COVID-19.
Nofal A, Fawzy MM, Abdelmaksoud A, El-Hawary EE.
J Dermatolog Treat. 2020 Aug 8:1-4. doi: 10.1080/09546634.2020.1808152. Online ahead of print. Commentary / recommendations.
https://doi.org/10.1080/09546634.2020.1808152

Response to "Patient preference for cellulitis treatment: at-home care is preferred to hospital-based treatment".
Shaw KS, Karagounis TK, Yin L, Gibbon G, Betensky RA, Lo Sicco KI, Femia AN.
J Am Acad Dermatol. 2020 Aug 7:S0190-9622(20)32360-4. doi: 10.1016/j.jaad.2020.07.120. Online ahead of print. Case review / audit.
https://doi.org/10.1016/j.jaad.2020.07.120

The COVID-19 outbreak negatively affects the delivery of care for patients with diabetic foot ulcers.
Liu C, You J, Zhu W, Chen Y, Li S, Zhu Y, Ji S, Wang Y, Li H, Li L, Fan S.
Diabetes Care. 2020 Aug 7:dc201581. doi: 10.2337/dc20-1581. Online ahead of print. Research study / case review.
https://doi.org/10.2337/dc20-1581

COVID-19 and immunosuppressive therapy in dermatology.
Schwartz RA, Pradhan S, Murrell DF, Jafferany M, Olisova OY, Lomonosov KM, Lotti T, Goldust M.
Dermatol Ther. 2020 Aug 7:e14140. doi: 10.1111/dth.14140. Online ahead of print. Review / recommendations.
https://doi.org/10.1111/dth.14140

Impact of the COVID-19 pandemic on chronic inflammatory dermatoses: Mixed messages regarding the dermatologist's point of view and the patient's concerns.
Fougerousse AC, Maccari F, Reguiai Z, Begon E, Pallure V, Taïeb C, Girard C, Mery-Bossard L.
Acta Derm Venereol. 2020 Jul 31. doi: 10.2340/00015555-3610. Online ahead of print. Commentary.
https://doi.org/10.2340/00015555-3610

COVID-19 and implications for dermatological and allergological diseases.
Buhl T, Beissert S, Gaffal E, Goebeler M, Hertl M, Mauch C, Reich K, Schmidt E, Schön MP, Sticherling M, Sunderkötter C, Traidl-Hoffmann C, Werfel T, Wilsman-Theis D, Worm M.
J Dtsch Dermatol Ges. 2020 Jul 27. doi: 10.1111/ddg.14195. Online ahead of print. Review.
https://doi.org/10.1111/ddg.14195

Male balding is a major risk factor for severe COVID-19.
Lee J, Yousaf A, Fang W, Kolodney M.
J Am Acad Dermatol. 2020 Jul 21:S0190-9622(20)32262-3. doi: 10.1016/j.jaad.2020.07.062. Online ahead of print. Cross-sectional study.
https://doi.org/10.1016/j.jaad.2020.07.062

Management of patients with Behçet's disease during the COVID-19 pandemic.
Dursun R, Temiz SA, Özer İ, Daye M, Ataseven A.
Dermatol Ther. 2020 Jul 25:e14063. doi: 10.1111/dth.14063. Online ahead of print. Retrospective cohort study.
https://doi.org/10.1111/dth.14063

Response to- management of leprosy patients in era of covid.
Kumar B, Narang T, Dogra S.
Dermatol Ther. 2020 Jul 23:e14052. doi: 10.1111/dth.14052. Online ahead of print. Commentary.
https://doi.org/10.1111/dth.14052

COVID-19 infection in patients with Sézary syndrome: report of two cases.
Gonzaga Y, Batista Fontes Santos M, Silva MM, Nucci M.
Dermatol Ther. 2020 Jul 23:e14042. doi: 10.1111/dth.14042. Online ahead of print. No abstract available. Case reports.
https://doi.org/10.1111/dth.14042

"Cell phone acne" epidemic during COVID-19 pandemic.
Singh M, Pawar M, Maheshwari A, Bothra A, Khunger N.
Clin Exp Dermatol. 2020 Jun 29. doi: 10.1111/ced.14360. [Epub ahead of print]. Case series.
https://doi.org/10.1111/ced.14360

Evaluation of the effects of COVID-19 pandemic on hair diseases through a web-based questionnaire.
Turkmen D, Altunisik N, Sener S, Colak C.
Dermatol Ther. 2020 Jun 28:e13923. doi: 10.1111/dth.13923. [Epub ahead of print]. Survey.
https://doi.org/10.1111/dth.13923

Epidermolysis bullosa and the COVID-19 pandemic: challenges and recommendations.
Vahidnezhad H, Moravvej H, Bahmanjahromi A, Youssefian L, Abdollahimajd F.
J Dermatolog Treat. 2020 Jun 26:1-6. doi: 10.1080/09546634.2020.1788701. [Epub ahead of print] No abstract available. Commentary & recommendations.
https://doi.org/10.1080/09546634.2020.1788701

Considerations of managing lichen planopilaris with hydroxychloroquine during the COVID-19 pandemic.
Dadkhahfar S, Araghi F, Tabary M, Moravvej H.
J Drugs Dermatol. 2020 Jun 1;19(6):679-680. No abstract available. Review / commentary.
https://jddonline.com/articles/dermatology/S1545961620P0679X

Facial Abrikosoff tumour: The role of the dermatologist during COVID-19 pandemic.
Orsini D, D'Arino A, Tedesco M, Cota C, Pigliacelli F, Assorgi C, Latini A, Cristaudo A, Morrone A.
Int Wound J. 2020 Jun 23. doi: 10.1111/iwj.13431. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/iwj.13431

Hygienic and cosmetic care habits in polish women during COVID-19 pandemic.
Mościcka P, Chróst N, Terlikowski R, Przylipiak M, Wołosik K, Przylipiak A.
J Cosmet Dermatol. 2020 Jun 23. doi: 10.1111/jocd.13539. [Epub ahead of print]. Survey.
https://doi.org/10.1111/jocd.13539

Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions.
Valent P, Akin C, Bonadonna P, Brockow K, Niedoszytko M, Nedoszytko B, Butterfield JH, Alvarez-Twose I, Sotlar K, Schwaab J, Jawhar M, Reiter A, Castells M, Sperr WR, Kluin-Nelemans HC, Hermine O, Gotlib J, Zanotti R, Broesby-Olsen S, Horny HP, Triggiani M, Siebenhaar F, Orfao A, Metcalfe DD, Arock M, Hartmann K.
J Allergy Clin Immunol. 2020 Jun 16. pii: S0091-6749(20)30839-3. doi: 10.1016/j.jaci.2020.06.009. [Epub ahead of print]. Review / recommendations.
https://doi.org/10.1016/j.jaci.2020.06.009

Observation and consideration on using of JAKi in clinical trials in times of COVID-19.
Yang J, Maher AM, Li Y, An X, Tao J.
Dermatol Ther. 2020 Jun 15. doi: 10.1111/dth.13831. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1111/dth.1383

Short-term stress-related increasing cases of alopecia areata during the COVID-19 pandemic.
Kutlu Ö, Aktaş H, İmren IG, Metin A.
J Dermatolog Treat. 2020 Jun 13:1-4. doi: 10.1080/09546634.2020.1782820. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1080/09546634.2020.1782820

Teledermatology for acne during COVID-19: high patients' satisfaction in spite of the emergency.
Ruggiero A, Megna M, Annunziata MC, Abategiovanni L, Scalvenzi M, Tajani A, Fabbrocini G, Villani A.
J Eur Acad Dermatol Venereol. 2020 Jun 13. doi: 10.1111/jdv.16746. [Epub ahead of print]. Prospective observational study.
https://doi.org/10.1111/jdv.16746

Cutaneous autoimmune diseases during COVID 19 pandemic.
Günther C, Aschoff R, Beissert S.
J Eur Acad Dermatol Venereol. 2020 Jun 13. doi: 10.1111/jdv.16753. [Epub ahead of print]. Review / commentary.
https://doi.org/10.1111/jdv.16753

Saving the diabetic foot during the COVID-19 pandemic: A tale of two cities.
Shin L, Bowling FL, Armstrong DG, Boulton AJM.
Diabetes Care. 2020 Jun 12. pii: dc201176. doi: 10.2337/dc20-1176. [Epub ahead of print]. Review & case reports.
https://doi.org/10.2337/dc20-1176

Diabetic foot ulceration in COVID-19 lockdown: cause for concern or unexpected benefit?
Lipscomb D, Smith AS, Adamson S, Rezazadeh EM.
Diabet Med. 2020 Jun 12. doi: 10.1111/dme.14340. [Epub ahead of print]. Commentary / audit.
https://doi.org/10.1111/dme.14340

Change of the diagnostic distribution in applicants to dermatology after COVID-19 pandemic: What it whispers to us?
Turan Ç, Metin N, Utlu Z, Öner Ü, Kotan ÖS.
Dermatol Ther. 2020 Jun 12:e13804. doi: 10.1111/dth.13804. [Epub ahead of print]. Cross-sectional study.
https://doi.org/10.1111/dth.13804

Recommendations on trichological treatments during COVID-19 pandemic.
Rossi A, Magri F, Caro G, Federico A, Di Fraia M, Muscianese M, Fortuna MC, Carlesimo M.
J Dermatolog Treat. 2020 Jun 10:1-20. doi: 10.1080/09546634.2020.1781046. [Epub ahead of print]. Review / recommendations.
https://doi.org/10.1080/09546634.2020.1781046

Post the pandemic: How will COVID-19 transform diabetic foot disease management?
Najafi B.
J Diabetes Sci Technol. 2020 Jun 9:1932296820930290. doi: 10.1177/1932296820930290. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1177/1932296820930290

Geriatric skin care in the era of COVID-19.
Golpanian RS, Yosipovitch G.J 
Am Geriatr Soc. 2020 Jun 7. doi: 10.1111/jgs.16627. [Epub ahead of print] No abstract available. Commentary / review.
https://doi.org/10.1111/jgs.16627

Cutaneous lupus erythematosus patients in a high-epidemic COVID-19 area, Bergamo, Italy.
Vezzoli P, Di Mercurio M, Carugno A, Gambini DM, Robustelli Test E, Imberti G, Castagna AF, Sena P.
Dermatol Ther. 2020 Jun 7. doi: 10.1111/dth.13776. [Epub ahead of print] No abstract available. Survey / cross-sectional study.
https://doi.org/10.1111/dth.13776

Challenges faced by patients with morphea in the era of SARS-CoV-2.
Shahidi Dadras M, Namazi N, Nikvar M, Abdollahimajd F.
J Dermatolog Treat. 2020 Jun 5:1-6. doi: 10.1080/09546634.2020.1775771. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1080/09546634.2020.1775771

Recommendations for management of diabetic foot ulcers during COVID-19 outbreak.
Kelahmetoglu O, Camlı MF, Kirazoglu A, Erbayat Y, Asgarzade S, Durgun U, Mehdizade T, Yeniocak A, Yildiz K, Sonmez Ergun S, Guneren E.
Int Wound J. 2020 Jun 5. doi: 10.1111/iwj.13416. [Epub ahead of print]. Review / recommendations.
https://doi.org/10.1111/iwj.13416

Management of diabetic persons with foot ulceration during COVID-19 health care emergency: effectiveness of a new triage pathway.
Marco M, Valentina I, Laura G, Roberto G, Luigi U.
Diabetes Res Clin Pract. 2020 Jun 1:108245. doi: 10.1016/j.diabres.2020.108245. [Epub ahead of print]. Cohort study.
https://doi.org/10.1016/j.diabres.2020.108245

Teledermatology for acne patients: how to reduce face-to-face visits during COVID-19 pandemic.
Villani A, Annunziata MC, Abategiovanni L, Fabbrocini G.
J Cosmet Dermatol. 2020 Jun 3. doi: 10.1111/jocd.13519. [Epub ahead of print]. Report / commentary.
https://doi.org/10.1111/jocd.13519

Psoriatic arthritis and COVID-19 pandemic: Consequences in medical treatment?
Wollina U, Fioranelli M, Goldust M, Lotti T.
Dermatol Ther. 2020 Jun 1:e13743. doi: 10.1111/dth.13743. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13743

Recommendations for diagnosis and treatment of onychomycosis during the COVID-19 pandemic.
Lipner SR, Ricardo JW.
Dermatol Ther. 2020 May 30:e13709. doi: 10.1111/dth.13709. [Epub ahead of print] No abstract available. Review / recommendations.
https://doi.org/10.1111/dth.13709

The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease.
Dursun R, Temiz SA.
Dermatol Ther. 2020 May 31:e13730. doi: 10.1111/dth.13730. [Epub ahead of print]. Retrospective case review.
https://doi.org/10.1111/dth.13730

COVID-19 and ectodermal dysplasias. Recommendations are necessary.
Callea M, Willoughby CE, Perry D, Holzer U, Fedele G, Cárdenas Tadich A, Cammarata-Scalisi F.
Dermatol Ther. 2020 May 30:e13702. doi: 10.1111/dth.13702. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13702

Impact of Covid 19 pandemic on obsessive compulsive and related disorder patients- Psychodermatological perspectives.
Hafi B, Uvais NA, Jafferany M, Afra TP, Muhammed Razmi T.
Dermatol Ther. 2020 May 30. doi: 10.1111/dth.13736. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13736

Palliative psychodermatology care during COVID-19 pandemic.
Hafi B, Uvais NA, Jafferany M, Afra TP, Muhammed RT.
Dermatol Ther. 2020 May 30. doi: 10.1111/dth.13732. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13732

Taking care of systemic sclerosis patients during COVID-19 pandemic: rethink the clinical activity.
Minniti A, Maglione W, Pignataro F, Cappadona C, Caporali R, Del Papa N.
Clin Rheumatol. 2020 May 27. doi: 10.1007/s10067-020-05191-4. [Epub ahead of print] Report / commentary.
https://doi.org/10.1007/s10067-020-05191-4

Response to: 'Are patients with systemic lupus erythematosus at increased risk for COVID-19?' by Favalli et al.
Mathian A, Amoura Z.
Ann Rheum Dis. 2020 May 25. pii: annrheumdis-2020-217859. doi: 10.1136/annrheumdis-2020-217859. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1136/annrheumdis-2020-217859

Are patients with systemic lupus erythematosus at increased risk for COVID-19?
Favalli EG, Gerosa M, Murgo A, Caporali R.
Ann Rheum Dis. 2020 May 25. pii: annrheumdis-2020-217787. doi: 10.1136/annrheumdis-2020-217787. [Epub ahead of print] No abstract available. Survey / cross-sectional study.
https://doi.org/10.1136/annrheumdis-2020-217787

Two false negative test results in a symptomatic patient with a confirmed case of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and suspected Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).
Lagziel T, Quiroga L, Ramos M, Hultman CS, Asif M.
Cureus. 2020 May 19;12(5):e8198. doi: 10.7759/cureus.8198. Case report.
https://doi.org/10.7759/cureus.8198

COVID-19 and herpes zoster co-infection presenting with trigeminal neuropathy.
de Freitas Ferreira ACA, Romão TT, SIlva Macedo Y, Pupe C, Nascimento OJ.
Eur J Neurol. 2020 May 24. doi: 10.1111/ene.14361. [Epub ahead of print]. Case report.
https://doi.org/10.1111/ene.14361

Androgenetic alopecia present in the majority of hospitalized COVID-19 patients - the "Gabrin sign".
Wambier CG, Vaño-Galván S, McCoy J, Gomez-Zubiaur A, Herrera S, Hermosa-Gelbard Á, Moreno-Arrones OM, Jiménez-Gómez N, González-Cantero A, Pascual PF, Segurado-Miravalles G, Shapiro J, Pérez-García B, Goren A.
J Am Acad Dermatol. 2020 May 21. pii: S0190-9622(20)30948-8. doi: 10.1016/j.jaad.2020.05.079. [Epub ahead of print] No abstract available. Cross-sectional study.
https://doi.org/10.1016/j.jaad.2020.05.079

Management of telogen effluvium during the Covid-19 emergency: Psychological implications.
Rivetti N, Barruscotti S.
Dermatol Ther. 2020 May 22:e13648. doi: 10.1111/dth.13648. [Epub ahead of print] No abstract available. Commentary / review.
https://doi.org/10.1111/dth.13648

Management of leprosy patients in the era of COVID19.
Abdelmaksoud A, Gupta SK.
Dermatol Ther. 2020 May 22:e13631. doi: 10.1111/dth.13631. [Epub ahead of print] No abstract available. Review / recommendations.
https://doi.org/10.1111/dth.13631

Immunosuppressive treatment for systemic sclerosis - therapeutic challenges during the COVID-19 pandemic.
Blicharz L, Czuwara J, Samochocki Z, Goldust M, Olszewska M, Rudnicka L.
Dermatol Ther. 2020 May 19:e13619. doi: 10.1111/dth.13619. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13619

Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients.
Fortuné C, Gietzen A, et al.; Scleroderma Patient-centered Intervention Network (SPIN); COVID-19 Patient Advisory Team.
J Psychosom Res. 2020 May 14:110132. doi: 10.1016/j.jpsychores.2020.110132. [Epub ahead of print]. Trial protocol.
https://doi.org/10.1016/j.jpsychores.2020.110132

Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19.
Galimberti F, McBride J, Cronin M, Li Y, Fox J, Abrouk M, Herbst A, Kirsner RS.
Clin Dermatol. 2020 May 14. doi: 10.1016/j.clindermatol.2020.05.003. [Epub ahead of print]. Review / recommendations.
https://doi.org/10.1016/j.clindermatol.2020.05.003

Could patients taking isotretinoin therapy be immune against SARS-COV-2?
Elgarhy LH.
Dermatol Ther. 2020 May 13. doi: 10.1111/dth.13573. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13573

Recommendations for treatment of nail lichen planus during the COVID-19 pandemic.
Ricardo JW, Lipner SR.
Dermatol Ther. 2020 May 10:e13551. doi: 10.1111/dth.13551. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13551

Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?
Kutlu Ö, Metin A.
Dermatol Ther. 2020 May 5:e13509. doi: 10.1111/dth.13509. [Epub ahead of print]. Case series.
https://doi.org/10.1111/dth.13509

Systemic isotretinoin therapy in the era of COVID19.
Abdelmaksoud A, Vestita M, El-Amawy HS, Ayhan E, An İ, Öztürk M, Goldust M.
Dermatol Ther. 2020 May 1:e13482. doi: 10.1111/dth.13482. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13482

Dermatology patients' knowledge and concerns regarding their immunomodulatory medication during the COVID-19 pandemic.
Keeling E, Daly S, McKenna DB.
Dermatol Ther. 2020 May 1:e13488. doi: 10.1111/dth.13488. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1111/dth.13488

Calm before the storm: understanding the role of JAK inhibitors in COVID-19.
Peterson D, Damsky W, King B.
J Am Acad Dermatol. 2020 Apr 25. pii: S0190-9622(20)30713-1. doi: 10.1016/j.jaad.2020.04.097. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.04.097

Chronic cutaneous ulcers management in dermatologic department during COVID-19 era.
Zagaria O, Ruggiero A, Cinelli E, Marasca C, Monfrecola A, Fabbrocini G.
Int Wound J. 2020 Apr 28. doi: 10.1111/iwj.13385. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/iwj.13385

Potential role of Janus kinase inhibitors in COVID-19.
Napolitano M, Fabbrocini G, Patruno C.
J Am Acad Dermatol. 2020 Apr 24. pii: S0190-9622(20)30714-3. doi: 10.1016/j.jaad.2020.04.098. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.04.098

Wound center without walls: The new model of providing care during the COVID-19 pandemic.
Rogers LC, Armstrong DG, Capotorto J, Fife CE, Garcia JR, Gelly H, Gurtner GC, Lavery LA, Marston W, Neville R, Nusgart M, Ravitz K, Woelfel S.
Wounds. 2020 Apr 24. pii: WNDS20200420-1. [Epub ahead of print]
https://www.woundsresearch.com/article/wound-center-without-walls-new-model-providing-care-during-covid-19-pandemic

Mass quarantine measures in the time of COVID-19 pandemic: psycho-social implications for chronic skin conditions and a call for qualitative studies.
Garcovich S, Bersani FS, Chiricozzi A, De Simone C.
J Eur Acad Dermatol Venereol. 2020 Apr 24. doi: 10.1111/jdv.16535. [Epub ahead of print]
https://doi.org/10.1111/jdv.16535

Phototherapeutic approach to dermatological patients during the 2019 coronavirus pandemic: Real-life data from the Italian Red Zone.
Pacifico A, Ardigò M, Frascione P, Damiani G, Morrone A.
Br J Dermatol. 2020 Apr 17. doi: 10.1111/bjd.19145. [Epub ahead of print]
https://doi.org/10.1111/bjd.19145

The use of Janus kinase inhibitors in the time of SARS-CoV-2.
Peterson D, Damsky W, King B.
J Am Acad Dermatol. 2020 Apr 9. pii: S0190-9622(20)30522-3. doi: 10.1016/j.jaad.2020.03.099. [Epub ahead of print] No abstract available.
https://doi.org/10.1016/j.jaad.2020.03.099

Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients.
Sawalha AH, Zhao M, Coit P, Lu Q.
Clin Immunol. 2020 Apr 7:108410. doi: 10.1016/j.clim.2020.108410. [Epub ahead of print]
https://doi.org/10.1016/j.clim.2020.108410 

 

Back to CEBD Coronavirus Dermatology Resource Homepage

Centre of Evidence Based Dermatology

The University of Nottingham
King's Meadow Campus
Lenton Lane
Nottingham, NG7 2NR


telephone: +44 (0) 115 823 1048
email:cebd@nottingham.ac.uk